In this month’s roundup, we cover topics including laboratory eligibility criteria as a potential barrier to clinical participation and the impact of cognitive dysfunction on survival in patients with hematologic cancers. Read on to find out more.
The phosphatidylinositol 3-kinase isoform p110δ inhibitor umbralisib has shown preliminary activity against relapsed or refractory hematologic malignancies, with fewer autoimmune-like toxicities than other drugs in its class, researchers report.
One in five patients with heavily pretreated, refractory multiple myeloma may respond to treatment with the selective exportin 1 inhibitor selinexor, plus low-dose dexamethasone, phase II study findings indicate.
The oral factor Xa inhibitor edoxaban is as good as subcutaneous dalteparin for the prevention of recurrent venous thromboembolism or major bleeding in patients with cancer, show results of the Hokusai VTE cancer trial.
US researchers have detailed the pathophysiology, clinical presentation, and management of breast implant-associated anaplastic large cell lymphoma in a move to educate healthcare professionals dealing with this rare but increasingly common diagnosis.
A study investigating whether azithromycin improves airflow decline–free survival following allogeneic hematopoietic stem cell transplantation was terminated early due to an unexpected increased risk for hematologic malignancy relapse, researchers report.